Low dose naltrexone has not been proven safe in pregnancy, but it has not been shown to be harmful either. Almost all the human evidence comes from small groups, and much of it from women on full-strength naltrexone for addiction rather than the tiny doses used for autoimmune conditions or pain. The reassurance that exists is real but indirect, so the choice usually comes down to weighing the unknowns against what stopping would cost you.
What the Human Evidence Shows So Far
Low dose naltrexone (LDN) is the same drug used for alcohol and opioid addiction, taken at a fraction of the dose, often 1.5 to 4.5 mg a day instead of 50 mg. No large, well-controlled studies have looked at LDN safety in pregnancy. Most of what exists is anecdotal reports and small case series.1Natural Endocrinology Specialists. Low Dose Naltrexone (LDN) and Pregnancy: Is It Safe for Expecting Mothers with Hashimoto’s? – Natural Endocrinology Specialists
One survey did ask women who took LDN while pregnant about their babies. Three babies in the LDN group and 2 in the comparison group had a birth anomaly, and every respondent in both groups reported a healthy child.2RRM Academy. Low Dose Naltrexone in Pregnancy That sounds good, but the survey came from an LDN advocacy group, and the differences between groups were too small to be sure of anything. It relied on women’s own reports and on who chose to answer, and a parent saying a child is healthy is not a medical exam.
Studies of higher-dose naltrexone add some reassurance. Reviews of naltrexone used for alcohol problems in pregnancy have not found substantial risk of birth defects or other serious consequences, though more research is needed.3PubMed. Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider? In a case series of women treated with naltrexone during pregnancy, there were no fetal anomalies and one preterm birth.4PubMed Central. Case series of individuals treated with naltrexone during pregnancy for opioid and/or alcohol use disorder A case series simply describes women who happened to be treated, with no unexposed group to compare against, so it can show that serious harm is not obvious but cannot show it is absent.
Compared with similar women on buprenorphine, babies exposed to naltrexone were born at similar ages and weights, and one had a mild kidney widening.5PubMed Central. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects A single mild kidney widening is the sort of finding that appears in pregnancies with no medication exposure, so one case does not point to a cause.
Most of this reassuring information concerns women taking naltrexone for addiction, with 50 mg pills or 380 mg monthly injections, many times an LDN dose. If a much larger dose has not shown a clear pattern of birth defects, that leans toward a lower dose being no worse. A lower dose probably means less drug reaching the baby, but lower doses may act on the body differently, so findings can’t simply be carried over. Women in addiction studies also differ in health and in other exposures, such as tobacco or other substances, which muddies what the results mean for an LDN user.
Small studies have another limit. A study of dozens of babies can’t detect a rare problem affecting one in a thousand. Not finding a signal is reassuring but is not proof of safety.
Does Naltrexone Reach the Baby
Yes. In women taking naltrexone, the drug and its breakdown product were found in cord blood and in babies’ blood in the first 48 hours after birth.6PubMed Central. Pharmacokinetics of Oral and Extended-release Naltrexone in Pregnant and Lactating Individuals and their Infants At delivery, levels in the cord ran about three-quarters of the mother’s on daily pills and about equal to the mother’s on the monthly injection.7PubMed Central. Pharmacokinetics of Oral and Extended-release Naltrexone in Pregnant and Lactating Individuals and their Infants Computer modeling of the monthly injection predicts the baby’s exposure rises as pregnancy goes on, possibly exceeding the mother’s in the third trimester.8PubMed Central. Physiologically based pharmacokinetic modeling of long‐acting extended‐release naltrexone in pregnant women with opioid use disorder A placenta model in the lab, though, let only a small fraction through over 8 hours, so estimates vary.9PubMed Central. Transport of Maternally Administered Pharmaceutical Agents Across the Placental Barrier In Vitro
The numbers disagree partly because they measure different things: cord blood readings come from real deliveries, the lab model uses donated placental tissue in a dish, and the computer model is a prediction built on assumptions. Daily pills and the monthly injection also release the drug in different patterns.
Many common medicines cross the placenta, and crossing alone does not mean harm. It does mean the baby gets its own exposure, so effects on development are a fair question to ask. The measured levels came from women on full-strength pills or injections, and an LDN dose is much smaller, so the amount reaching a baby would likely be far lower.
How Babies Did After Birth and Beyond
Newborn withdrawal is a cluster of jitteriness, poor feeding and crying in babies exposed to opioids before birth. In one group of 68 naltrexone-exposed babies, 7.5% had newborn withdrawal, versus about 52% with methadone and 42% with buprenorphine.10PubMed. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates Naltrexone-exposed babies also went home sooner, after about 5.5 days versus 11.3 with methadone.11PubMed. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates None of the infants in a naltrexone case series developed newborn withdrawal.12PubMed Central. Case series of individuals treated with naltrexone during pregnancy for opioid and/or alcohol use disorder
These babies were compared with opioid-exposed babies, not with unexposed babies. Naltrexone blocks opioids rather than acting like one, so withdrawal was not expected from it. An LDN user’s real question is how her baby compares with an unexposed baby, and these studies do not answer that.
In a very small comparison, naltrexone-exposed newborns scored somewhat more alert and excitable and lower on attention on a newborn behavior exam.13PubMed Central. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy The differences were modest, and with such tiny groups, one or two unusual babies can shift an average, so they may be chance. At about one year, development scores did not differ from buprenorphine-exposed babies, though only 3 naltrexone babies were checked.14PubMed Central. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy That is too few to show reliably whether development is the same or different. No studies follow LDN-exposed children into school age.
Why Some Experts Stay Cautious
The body makes its own opioid-like chemicals, and in the developing brain they slow cell growth and branching. These natural opioids help set how fast and how much brain cells grow.15Georgetown Medical Review. The Effects of Opioids During Pregnancy: A Literature Review In young rats, blocking them made brain cell branches grow 51% to 136% longer.16PubMed. Endogenous opioids regulate dendritic growth and spine formation in developing rat brain
Animal pregnancy findings point both ways. Rats given high daily doses throughout pregnancy had larger pups, 36% heavier by weaning, with larger organs.17PubMed. Chronic exposure to the opioid antagonist naltrexone during pregnancy: maternal and offspring effects Rats given slow-release naltrexone had pups about 11% lighter at birth, with brain chemistry and behavior changes in adulthood.18PubMed Central. Maternally Administered Sustained-Release Naltrexone in Rats Affects Offspring Neurochemistry and Behaviour in Adulthood Reviewers note these developmental changes in animals raise concern for human use.19PubMed Central. The Effects of Maternally Administered Methadone, Buprenorphine and Naltrexone on Offspring: Review of Human and Animal Data
How far this applies to you is unclear. The rats got doses designed to block opioid receptors all day, unlike LDN’s brief nightly block. Effects in opposite directions, bigger pups in one study and smaller in another, show the system is sensitive, not that harm occurs in people. Human studies so far have not shown matching growth problems in babies, though they are small.
The leading theory is that LDN briefly blocks opioid receptors, and the body responds by making more of its own opioids. That rebound involves the same natural opioid system that helps pace fetal growth and brain development. So the theory behind LDN’s possible benefit is also the reason some experts urge caution.
Should You Keep Taking It or Stop
For women stable on naltrexone before pregnancy, obstetric guidance says to continue or stop after a careful talk weighing limited safety data against relapse risk.20Substance Abuse and Mental Health Services Administration. Treatment of Opioid Use Disorder Before, During, and After Pregnancy Experts say women stable on the monthly injection could reasonably continue through pregnancy, but starting it during pregnancy isn’t recommended.21PubMed Central. Caring for Pregnant Women with Opioid Use Disorder in the USA: Expanding and Improving Treatment Many doctors apply similar reasoning to LDN.
Fertility is another route in. In one study of women with repeated failed embryo transfers, LDN was linked to a thicker uterine lining, fewer immune markers and higher pregnancy rates.22Репродуктивне здоров. The effect of low-dose naltrexone on immunological infertility in women with recurrent implantation failure So some women start LDN to conceive and then face the continue-or-stop question early.
Stopping suddenly is not dangerous the way stopping opioids can be, but symptoms may return within weeks. Untreated autoimmune flares can themselves affect a pregnancy, so stopping is not automatically the safer choice. LDN is often prescribed by a different doctor than your obstetrician, so tell both and bring the exact dose and pharmacy name to your first prenatal visit.
Questions worth bringing:
- How active is my condition now, and what did it do last time I was off LDN? A history of quick flares weighs toward continuing.
- Would stopping mean switching to a drug with better pregnancy data, or one with worse?
- If I continue, should the dose or timing change?
- Should I stop at a positive test, at a set week, or not at all?
Labor, Epidurals and Pain Medicine
Naltrexone blocks opioids, which can make opioid pain medicines work less well while it’s in your system. But an LDN dose is mostly gone within several hours, and blocking strong opioids takes doses around 50 to 150 mg. People who took LDN shortly before needing an epidural have either waited or had non-opioid medicines used instead.23LDN Research Trust. LDN Community Epidurals rely mainly on local anesthetics, which are not opioids, so they can still work, though opioids often added to epidurals may work less well. Tell your anesthesia team when you last took LDN.
Write your LDN dose and usual time into your birth plan. Ask your doctor whether to skip doses near your due date or before a scheduled C-section.
LDN is usually made by a compounding pharmacy, which mixes custom-strength doses not sold as standard pills. Imprecise measuring can cause meaningful variation in strength.24Medisca. LDN Risks: Dangers of At-Home Compounding In pregnancy, use a licensed compounding pharmacy rather than home-mixed doses.
If you plan to breastfeed, ask your pediatrician about continuing LDN while nursing, since data are limited.